Literature DB >> 19965681

Induction of nitric oxide by erythropoietin is mediated by the {beta} common receptor and requires interaction with VEGF receptor 2.

Larysa Sautina1, Yuri Sautin, Elaine Beem, Zhuo Zhou, Anna Schuler, Jennafer Brennan, Sergey I Zharikov, Yanpeng Diao, Jorg Bungert, Mark S Segal.   

Abstract

Vascular endothelial growth factor (VEGF) and erythropoietin (EPO) have profound effects on the endothelium and endothelial progenitor cells (EPCs), which originate from the bone marrow and differentiate into endothelial cells. Both EPO and VEGF have demonstrated an ability to increase the number and performance properties of EPCs. EPC behavior is highly dependent on nitric oxide (NO), and both VEGF and EPO can stimulate intracellular NO. EPO can bind to the homodimeric EPO receptor (EPO-R) and the heterodimeric receptor, EPO-R and the common beta receptor (betaC-R). Although VEGF has several receptors, VEGF-R2 appears most critical to EPC function. We demonstrate that EPO induction of NO is dependent on the betaC-R and VEGF-R2, that VEGF induction of NO is dependent on the expression of the betaC-R, and that the betaC-R and VEGF-R2 interact. This is the first definitive functional and structural evidence of an interaction between the 2 receptors and has implications for the side effects of EPO.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965681     DOI: 10.1182/blood-2009-04-216432

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  Non-erythroid effects of erythropoietin.

Authors:  Murat O Arcasoy
Journal:  Haematologica       Date:  2010-11       Impact factor: 9.941

2.  Enhanced brain release of erythropoietin, cytokines and NO during carotid clamping.

Authors:  Stephana Carelli; Giorgio Ghilardi; Paola Bianciardi; Elisa Latorre; Federico Rubino; Marina Bissi; Anna Maria Di Giulio; Michele Samaja; Alfredo Gorio
Journal:  Neurol Sci       Date:  2015-10-22       Impact factor: 3.307

Review 3.  Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?

Authors:  Carla Cerami Hand; Michael Brines
Journal:  J Investig Med       Date:  2011-10       Impact factor: 2.895

Review 4.  The receptor that tames the innate immune response.

Authors:  Michael Brines; Anthony Cerami
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

5.  Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells.

Authors:  Stefan Bohr; Suraj J Patel; Radovan Vasko; Keyue Shen; Arvin Iracheta-Vellve; Jungwoo Lee; Shyam Sundhar Bale; Nilay Chakraborty; Michael Brines; Anthony Cerami; Francois Berthiaume; Martin L Yarmush
Journal:  J Mol Med (Berl)       Date:  2014-11-06       Impact factor: 4.599

Review 6.  Response of the cerebral vasculature following traumatic brain injury.

Authors:  Arjang Salehi; John H Zhang; Andre Obenaus
Journal:  J Cereb Blood Flow Metab       Date:  2017-04-05       Impact factor: 6.200

7.  Chronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction-dilated cardiomyopathy.

Authors:  Ismayil Ahmet; Hyun-Jin Tae; Michael Brines; Anthony Cerami; Edward G Lakatta; Mark I Talan
Journal:  J Pharmacol Exp Ther       Date:  2013-04-12       Impact factor: 4.030

Review 8.  Vascular growth factors in neuropsychiatry.

Authors:  Samuel S Newton; Neil M Fournier; Ronald S Duman
Journal:  Cell Mol Life Sci       Date:  2013-03-12       Impact factor: 9.261

9.  Erythropoietin increases macrophage-mediated T cell suppression.

Authors:  Michelle A Wood; Naomi Goldman; Kelley DePierri; John Somerville; James E Riggs
Journal:  Cell Immunol       Date:  2016-05-27       Impact factor: 4.868

Review 10.  Revisiting the role of erythropoietin for treatment of ocular disorders.

Authors:  S L Shirley Ding; S N Leow; R Munisvaradass; E H Koh; M L C Bastion; K Y Then; S Kumar; P L Mok
Journal:  Eye (Lond)       Date:  2016-06-10       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.